奥沙利铂联合方案介入治疗肝癌的研究

The study of oxaliplatin combined rigimen in the treatment of liver cancer with interventional therapy

目的评价奥沙利铂方案介入治疗肝癌的安全性和疗效。方法经肝动脉灌注奥沙利铂,氟脲苷(FUDR),丝裂霉素(MMC),碘油和明胶海绵颗粒,治疗前后做肝肾功能、血常规和肝脏B超或CT检查并与顺铂方案对照评价其安全性和疗效。结果采用奥铂方案治疗后两周内患者ALT值,总胆红素值和白细胞数升高,差异有显著性(P<0.05)一月后恢复到治疗前水平,差异无显著性(P>0.05)。尿素氮值、肌酐值、红细胞数、血小板数与治疗前比较差异无显著性(P>0.05),与顺铂方案对照,除肌酐值用顺铂方案治疗后有明显升高,差异有显著性(P<0.05)外,余差异无显著性(P>0.05)。与顺铂方案比较近期疗效无明显差异(P>0.05)。结论采用奥铂方案对肝功能和血液系统有一定影响,但与顺铂方案比较无明显差异,其对肾功能无影响,较顺铂方案为优,对部分肝癌患者有一定疗效。

OBJECTIVE To evaluate the effect and safety of interventional therapy with oxaliplatin plan for liver cancer. METHODS The patients with liver cancer were hepatic artery perfusioned with oxaliplatin, FUDR, MMC, lipiodol, granule of gelfoam. The liver function, renal function, blood routine, USG or CT exam of liver were tested before and after treatment and the results were compared with the CDDP plan for evaluate the effect and safety. RESULTS The ALT, bilirubin, leukocyte count were went up （P 〈 0.05） in two weeks and returned to level （P 〉 0.05） of before treatment after a month when the patients treated with oxaliplatin plan. The urea nitrogen, creatinine, red blood cell, blood platelet count did not change obviously. They were about the same （P 〉 0.05） as the CDDP plan except creatinine count was went up （ P 〈 0.05） in the CDDP plan. The effects of treatment were about the same （P 〉 0.05） as the CDDP plan. CONCLUSION The liver function and blood system are influenced with oxaliplatin plan, but it was about the same as CDDP plan. It doesnt influence renal function. It is an effective regimen for the part of patients with liver cancer.